Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc. (ACXP) priced its initial public offering on Jun 28, 2021 at $6.00 per share, within its $5.00–$7.00 range, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $57.2M. Alexander Capital was lead-left underwriter, joined by Network 1 and Financial. Mintz advised the company and Sullivan & Worcester advised the underwriters.

Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a new class of antibiotics for infections caused by priority bacterial pathogens named by the WHO, CDC and FDA, in response to the worldwide crisis of antimicrobial resistance.

Status

IPO

Ticker

ACXP

Exchange

Nasdaq Capital Market

Priced

Jun 28, 2021

IPO price

$6.00

Price range

$5.00–$7.00

Market cap at IPO price

$57.2M

First filed

May 27, 2021

Underwriters

Alexander Capital, Network 1 and Financial

Company counsel

Mintz

Underwriters' counsel

Sullivan & Worcester

Sector

Biotech & pharma

Country / state

NY

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.